These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30711416)

  • 1. A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C.
    Koh C; Dubey P; Han MAT; Walter PJ; Garraffo HM; Surana P; Southall NT; Borochov N; Uprichard SL; Cotler SJ; Etzion O; Heller T; Dahari H; Liang TJ
    Antiviral Res; 2019 Mar; 163():149-155. PubMed ID: 30711416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.
    He S; Lin B; Chu V; Hu Z; Hu X; Xiao J; Wang AQ; Schweitzer CJ; Li Q; Imamura M; Hiraga N; Southall N; Ferrer M; Zheng W; Chayama K; Marugan JJ; Liang TJ
    Sci Transl Med; 2015 Apr; 7(282):282ra49. PubMed ID: 25855495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
    Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.
    Andersohn F; Claes AK; Kulp W; Mahlich J; Rockstroh JK
    BMC Infect Dis; 2016 Jan; 16():10. PubMed ID: 26753774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
    J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
    Fernández-Rodríguez CM; Morillas RM; Masnou H; Navarro JM; Bárcena R; González JM; Martín-Martín L; Poyato A; Miquel-Planas M; Jorquera F; Casanovas T; Salmerón J; Calleja JL; Solà R; Alonso S; Planas R; Romero-Gomez M
    Gastroenterol Hepatol; 2014 Jan; 37(1):1-8. PubMed ID: 24360571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
    Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
    AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.
    Hu Z; Rolt A; Hu X; Ma CD; Le DJ; Park SB; Houghton M; Southall N; Anderson DE; Talley DC; Lloyd JR; Marugan JC; Liang TJ
    Cell Chem Biol; 2020 Jul; 27(7):780-792.e5. PubMed ID: 32386595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
    Talal AH; Dumas EO; Bauer B; Rejman RM; Ocque A; Morse GD; Lucic D; Cloherty GA; King J; Zha J; Zhang H; Cohen DE; Shulman N; Pawlotsky JM; Hézode C
    J Infect Dis; 2018 Jan; 217(3):474-482. PubMed ID: 29228392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
    Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
    Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
    Flisiak R; Kawazoe S; Znoyko O; Assy N; Gadano A; Kao JH; Lee KS; Zwirtes R; Portsmouth S; Dong Y; Xu D; Kumada H; Srinivasan S
    J Interferon Cytokine Res; 2016 Nov; 36(11):635-643. PubMed ID: 27327078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
    Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S
    J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin.
    Conti F; Vukotic R; Lorenzini S; Riili A; Cursaro C; Scuteri A; Loggi E; Galli S; Furlini G; Bernardi M; Andreone P
    Ann Hepatol; 2014; 13(2):196-203. PubMed ID: 24552861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.